Vimarsana
Biggest News Aggregation in the World

Mutant Cancers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mutant Cancers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mutant Cancers Today - Breaking & Trending Today

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - Vimarsana News

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Published: January 10, 2024

SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that the European Commission granted...

Source: marketscreener.com
Related Topics:
Schleswig HolsteinCharles BaumMartin ReckUnion RegisterCommittee For Medicinal Products Human UseEuropean UnionPrnewswire Mirati Therapeutics IncExchange CommissionEuropean Medicines AgencyMirati Therapeutics IncEuropean CommissionLung Clinic GrosshansdorfMedicinal ProductsHuman UseMirati TherapeuticsProduct CharacteristicsTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure - Vimarsana News

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

Published: November 10, 2023

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...

Source: marketscreener.com
Related Topics:
United KingdomSchleswig HolsteinMartin ReckAlan SandlerCommittee For Medicinal Products Human UseHealthcare Products Regulatory AgencyExchange CommissionEuropean Medicine AgencyMirati Therapeutics IncPrnewswire Mirati Therapeutics IncEuropean CommissionEuropean UnionMirati Therapeutic IncBristol Myers Squibb CompanyMedicinal ProductsHuman UseMirati TherapeuticsLung Clinic GrosshansdorfMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical Models
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - Vimarsana News

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Published: November 4, 2023

SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare...

Source: marketscreener.com
Related Topics:
United KingdomGreat BritainAlan SandlerHealthcare Products Regulatory AgencyExchange CommissionPrnewswire Mirati Therapeutics IncMirati Therapeutics IncBristol Myers Squibb CompanyMirati Therapeutic IncUniversity Hospital BirminghamMirati TherapeuticsConsultant Medical OncologistSafety InformationProduct CharacteristicsMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - Vimarsana News

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Published: November 3, 2023

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and...

Source: prnewswire.com
Related Topics:
United KingdomGreat BritainAlan SandlerUniversity Hospital BirminghamHealthcare Products Regulatory AgencyPrnewswire Mirati Therapeutics IncMirati Therapeutics IncExchange CommissionMirati Therapeutic IncBristol Myers Squibb CompanyMirati TherapeuticsConsultant Medical OncologistSafety InformationProduct CharacteristicsMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation - Vimarsana News

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation

Published: July 21, 2023

SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced the European Medicine Agency's Committee for...

Source: marketscreener.com
Related Topics:
United StatesExchange CommissionCommittee For Medicinal Products Human UsePrnewswire Mirati Therapeutics IncEuropean Medicine AgencyMirati Therapeutics IncEuropean UnionMedicinal ProductsHuman UseConditional Marketing Authorisation ApplicationConditional MarketingConditional Marketing AuthorisationDavid MeekMirati TherapeuticsAccelerated ApprovalTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April